Sign up Calendar Latest Topics
 
 
 


Reply
  Author   Comment  
SoCalLisa

Avatar / Picture

Goddess Forever
Registered:
Posts: 2,134
Reply with quote  #1 

 
 
 
   

 
 

 
 

   
Bone-building drugs seem to cut risk that breast cancer returns

Oncologists look to further studies

By Marilynn Marchione
ASSOCIATED PRESS

June 1, 2008

CHICAGO – A drug to prevent bone loss during breast cancer treatment also substantially cut the risk the cancer would return, results that left doctors excited about a possible new way to fight the disease.

It's the first large study to affirm wider anti-cancer hopes for Zometa and other bone-building drugs called bisphosphonates. Zometa, made by Novartis AG, is used for cancers that have spread to the bone.

The study was sponsored by Zometa's maker, Swiss-based Novartis, and British-based AstraZeneca PLC, which makes Arimidex, the brand name of anastrozole, also used in the treatment of breast cancer in post-menopausal women. The study was led by Dr. Michael Gnant of the Medical University of Vienna, who consults for the companies and several other breast cancer drugmakers.

The study involved 1,800 premenopausal women taking hormone treatments for early-stage breast cancer. Zometa cut by one-third the chances that cancer would recur – in their bones or anywhere else.

“This is an important finding. It may well change practice,” said Dr. Claudine Isaacs, director of the clinical breast cancer program at Georgetown University's Lombardi Cancer Center.

About three-fourths of breast cancers occur in women after menopause. Zometa may help them, too, but it hasn't been tested in that age group.

Gnant reported his study yesterday at an American Society of Clinical Oncology conference in Chicago.

If a second, ongoing study also finds a benefit, doctors predict Zometa will be quickly tested against other cancers that tend to spread, or metastasize, to bones, such as prostate and kidney cancer.

“Hugely important is whether this has to do with the fact that it just makes the bone hostile, somehow, to metastasis, or if there is a more global anti-metastasis effect,” said the oncology group's president, Dr. Nancy Davidson of Johns Hopkins University. “Either of those would be good and would teach us a lot about what to do next.”

Breast cancer is the most common cancer in women. About 184,450 cases and 40,930 deaths from the disease are expected in the United States this year.

Standard treatments are surgery, chemotherapy, radiation and hormone-blocking drugs if the tumors are like those in the study – helped to grow by estrogen or progesterone.

The hormone-blockers often weaken bones, so bisphosphonates such as the osteoporosis pill Fosamax have become increasingly popular to treat this side effect. Using them to treat the cancer is a very different approach.

Lab studies hinted that it would work, and Gnant's is the first to test it in a large group of breast cancer patients.

All had surgery to remove their tumors and were taking hormone-blocking drugs – goserelin plus either tamoxifen or anastrozole – treatments that made them menopausal. Half also were given infusions of Zometa once every six months.

The women were treated for three years and studied for two more. By then, 6 percent of those given Zometa had suffered a relapse or died, compared with 9 percent of the others. That translated to a 36 percent decline in risk.

Sixteen women given Zometa died versus 26 of the others – a difference that could have occurred by chance, but an encouraging trend doctors hope will mean better survival as the groups are followed for a longer time.

There were no big differences in serious side effects, though minor ones such as fever and bone and joint pain were more common among women given Zometa. Two percent of all study participants developed a rapid heartbeat, but only three were hospitalized – two on Zometa and one of the others. With doctor fees, a Zometa treatment can run more than $1,200.

 


© Copyright 2007 Union-Tribune Publishing Co. ? A Copley Newspaper Site
 
 


__________________
"One's mind, once stretched by a new idea, never regains its original dimensions."
-Oliver Wendell Holmes
nosurrender

Avatar / Picture

Moderator
Registered:
Posts: 7,476
Reply with quote  #2 
I am speaking to my onc about starting this now. I have been following it for a while. Thank you so much Lisa for posting it!

__________________


WE WILL PREVAIL





FLLoriK

Angel
Registered:
Posts: 568
Reply with quote  #3 

I have been on Zometa for 2 years now. I have it IV every month but some doctors feel that every 3 months is sufficent. There is a chance of getting some SE with your jaw.  I'm sure someone else will come along w/more info on this.  

SoCalLisa

Avatar / Picture

Goddess Forever
Registered:
Posts: 2,134
Reply with quote  #4 
I know the risk of jaw necrosis with this and am wondering if it is worth the risk..a balancing act that is for sure..

__________________
"One's mind, once stretched by a new idea, never regains its original dimensions."
-Oliver Wendell Holmes
nosurrender

Avatar / Picture

Moderator
Registered:
Posts: 7,476
Reply with quote  #5 
I just had my first Dexa scan today as a baseline since I started Femara last month.
I was so surprised to find out I have osteopenia. ( I can't spell it.) I was surprised because I am not petite or frail, I am very active, I work out, do weights, the whole thing.
The doc told me that because of chemo, the steroids during chemo and even the synthroid I have been on, has caused the bone loss.
This will be something I will discuss with my onc.  If zometa can reverse the osteopenia and help prevent mets- then I  will take it.

Lori, how are you feeling? I heard that the zometa schedule of once every three months greatly reduces the jaw necrosis issue.


__________________


WE WILL PREVAIL





FLLoriK

Angel
Registered:
Posts: 568
Reply with quote  #6 

I have had bone mets progression on Zometa. Not to be "down" but take every thing with a grain of salt! 

Previous Topic | Next Topic
Print
Reply

Quick Navigation:

Easily create a Forum Website with Website Toolbox.